Biocon Limited is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Overview:
Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases to provide access to affordable treatment to patients across the global.
Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR® , for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India.
With a risk balanced business model comprising small molecules, novel molecules, biosimilars, branded formulations and research services, Biocon has evolved into an emerging global enterprise serving its partners and customers in over 70 countries
Shared 3 months ago
645 views
Shared 6 months ago
534 views
Shared 9 months ago
932 views
Shared 11 months ago
71 views
Shared 1 year ago
758 views
Shared 1 year ago
79 views
Shared 1 year ago
4.7K views
Shared 1 year ago
613 views
Shared 1 year ago
1.1K views
Shared 1 year ago
1.5K views
Shared 2 years ago
1.8K views
Shared 2 years ago
1K views
Shared 2 years ago
659 views
Kiran Mazumdar - Shaw,Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY23 Results
Shared 2 years ago
698 views
Shared 2 years ago
243 views
Shared 3 years ago
894 views
Shared 3 years ago
308 views
Shared 3 years ago
953 views
Shared 3 years ago
5.5K views
Shared 3 years ago
7.2K views
Shared 3 years ago
289 views
Shared 3 years ago
1.5K views
Shared 3 years ago
2.2K views
Shared 3 years ago
590 views
Shared 3 years ago
353 views
Shared 4 years ago
1K views
Shared 4 years ago
89 views
Shared 4 years ago
109 views